【中国生物制药(01177.HK)：库莫西利胶囊一线治疗乳腺癌新适应症上市申请获受理】智通财经APP讯，中国生物制药(01177.HK)发布公告，集团自主研发的CDK2/4/6抑制剂库莫西利胶囊“TQB3616”联合氟维司群注射液用于既往未经治疗的HR阳性、HER2阴性(HR+/HER2-)局部晚期或转移性乳腺癌，已向中国国家药品监督管理局药品审评中心(CDE)提交新适应症上市申请，并获得受理。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.